Pathology Laboratory - The pathological examination is crucial for an accurate diagnosis and the possible formulation or modification of the treatment of patients.
Genekor’s pathology laboratory guarantees high-quality services for the accurate diagnosis, prognosis and treatment of patients. With years of experience and qualified staff, we will provide reliable and valid results that support the best possible care for your patients.
(as prognostic and/or predictive markers) carried out at the Genekor Pathology Laboratory
| EXAMINATION | TYPE OF CANCER |
|---|---|
| FRα (FOLR1) | ovarian cancer |
| Claudin 18.2 | stomach cancer |
| MMR | endometrial/colon cancer |
| p53 | endometrial cancer |
| ER/PR/HER2 (clone 4B5) /Ki-67 | breast cancer |
| HER2 (clone 4B5) | various types of cancer |
| DISH (Dual in situ hybridization) σε HER2 2+ | |
| ALK | lung cancer |
| PD-L1 | various types of cancer |
In the new prime DX® test, the following predictive immunohistochemical markers can be added
| PD-L1 |
| HER2 overexpression |
| FRα for ovarian cancer |
| Claudin 18.2 for gastric and gastroesophageal junction adenocarcinoma |
| Cancer Type | IHC Panel | TAT |
|---|---|---|
| Gastric Cancer Panel | HER2 IHC, MMR IHC, Claudin 18.2 IHC, PD-L1 IHC | 3 working days |
| Ovarian Cancer | FOLR-1 IHC & HER2 IHC | 3 working days |
| Panels for Endometrial Cancer | ||
| A. | Pole exons 9-14 by NGS, MMR by IHC, P53 by IHC, L1CAM IHC | 10 working days |
| B. | Pole exons 9-14 by NGS, MMR by IHC, P53 by IHC, L1CAM IHC, HER2 IHC | 10 working days |
The FRα test is performed for the administration of mirvetuximab soravtansine and is aimed at patients with platinum-resistant ovarian cancer who are FRα-positive and have received 1-3 lines of therapy.
On September 19, 2024, the EMA issued a positive opinion for the administration of mirvetuximab soravtansine to patients with FRα-positive, platinum-resistant ovarian cancer who have received 1-3 lines of therapy, based on the phase III MIRASOL study.
In the US mirvetuximab soravtansine is FDA approved since March 2024.
The determination of FOLR1 (FRα) is carried out immunohistochemically on biopsy material, surgical specimens, or tissue embedded in paraffin blocks.The Ventana BenchMark Ultra automated platform is used.
In clinical practice, the sample is considered FOLR1 (FRα) positive if the neoplastic cells show moderate (2+) to intense (3+) complete or incomplete membrane staining in 75% or more of the sample. The sample is acceptable if it contains at least one hundred viable cancer cells. A positive external control is used.
Claudin 18.2 (CLDN 18.2) test is used to determine eligibility for the administration of Zolbetuximab alongside chemotherapy in patients with advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.
The EMA on September 20 approved Zolbetuximab for patients with HER2 negative/Claudin18.2 positive advanced or metastatic gastric adenocarcinoma and gastroesophageal junction as first-line therapy along with chemotherapy based on the phase III GLOW and SPOTLIGHT studies. In the US, Zolbetuximab recently received FDA approval (18 October 2024). Additionally, new studies on Claudin 18.2-positive patients with advanced or metastatic gastric and gastroesophageal junction adenocarcinoma were presented at this year’s ESMO (ESMO POSTERS1,2,3)
The Claudin 18.2 biomarker also serves as a prognostic marker in pancreatic cancer. At ESMO, the design of phase II randomized GLEAM study was presented, examining the administration of Zolbetuximab alongside chemotherapy in patients with pancreatic cancer. In this study, 27.7% of patients showed Claudin 18.2 positivity (≥ 75%).
Claudin 18.2 is determined immunohistochemically on biopsy material, surgical specimens, or tissues embedded in paraffin blocks for stomach and gastroesophageal junction adenocarcinomas. The automated Ventana BenchMark Ultra platform is used.
According to recent studies, moderate (2+) to strong (3+) complete or incomplete membrane immunohistochemical expression in neoplastic cells, with a percentage of at least 75%, is considered positive expression. An external positive control is used.
He studied medicine in Italy (University of Cagliari, Sardinia). As an unqualified doctor, he worked from 2009 to 2012 at the Naval Hospital of Crete, the General Hospital of Chania, the Health Centre of Kissamos, the rural clinic of Kolimbari, the private “Vittorakis Polyclinic” in Platanias and the “Revival” Rehabilitation Centre in Drama. He specialized in Pathological Anatomy at the “Theagenio” Cancer Hospital of Thessaloniki from 2012 to 2017. As a pathologist, he worked from 2017 to 2023 at the “Medical Inter-Balkan Hospital of Thessaloniki” and for almost one year at the private Pathology Laboratory “Istotypos”.
She received her Doctor of Medicine from School of Medicine at the University of Tashkent and completed her residency training in Pathology at the Department of Pathology and the Department of Cytology at “Theagenio” Cancer Hospital of Thessaloniki. She served for sixteen years as a Pathologist in the same Hospital. During that time, she participated with abstracts in Greek and International seminars and conferences.
She is a member of the Hellenic Society of Pathology, the European Society of Pathology and a member of Hellenic Cancer Research Society.
Persefoni Xirou studied medicine in Aristotle University of Thessaloniki, graduating with honors. She received the title of Specialist in Pathology in 1996 (Residency training: 4 years in Surgical Pathology and 1 year in Cytology). She worked as a Surgical Pathologist for almost 25 years in different public Greek hospitals (General Hospital of Volos, Agios Savvas Cancer Hospital, Papageorgiou General Hospital, Theagenion Cancer Hospital) and for 8 months in private practice. Persefoni Xirou was appointed as an international observer (from November 11 through December 6, 2019) in the subspecialty of Gastrointestinal and Thoracic in the Department of Pathology at Memorial Sloan Kettering Cancer Center under the supervision of Dr. Jinru Shia and Dr. William Travis, Program Director. She participated in a large number of national and international congresses/seminars (as attendant and with abstracts) and she has 87 presentations as invited speaker in national meetings. She is member of the Greek and European Societies of Pathology, of Greek Society of Cancer Research and of United States and Canadian Academy of Pathology (USCAP).
He studied at the Department of Medical Laboratories of the Technical University of Larissa and then passed qualifying exams and entered the Medical School of the Aristotle University of Thessaloniki.
After graduation, he was a rural doctor at the K.Y. of Farsala. Subsequently, he started and completed the specialty of Pathological Anatomy at the “Theagenio” Hospital.
He worked for 5 years at the A.E. Historiology Department specializing exclusively in the Macroscopic Department.
To find out more or to schedule a test, contact the:
our scientific staff at +30 2316003677
Address: E. Antistaseos 72 Eantos, 55133, Kalamaria, Thessaloniki